ResearcherThe University of AdelaideActive in the last 2 years
Eva Bezak
Matched on ORCID iD 0000-0002-1315-1735; OpenAlex author ID A5027460327. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 0, last author 8)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 6
2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 8
- Modelling of dose-escalated proton beam therapy for Locally Advanced Pancreatic Cancer using simulated phantoms. Last author DOI 10.1016/j.ejmp.2026.105758↗
- Modelling the impact of tumour hypoxia on proton therapy and concurrent chemotherapy on locally advanced pancreatic cancer-insights from anin silicostudy. Last author DOI 10.1088/1361-6560/ae273b↗
- In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer. Last author DOI 10.1186/s41181-023-00204-4↗
- Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration. Last author DOI 10.1186/s41181-023-00209-z↗
- Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cells11192983↗
- Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer. Last author DOI 10.3390/cancers12010163↗
- Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature. Last author DOI 10.3390/cancers12020481↗
- The Expression Profile and Textural Characteristics of C595-Reactive MUC1 in Pancreatic Ductal Adenocarcinoma for Targeted Radionuclide Therapy. Last author DOI 10.3390/cancers13010061↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ashleigh Hull · 5 shared papers, 2020–2023 · strength 0.86
- Paper In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer. DOI 10.1186/s41181-023-00204-4↗
- Paper Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessme… DOI 10.1186/s41181-023-00209-z↗
- Paper Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Duct… DOI 10.3390/cells11192983↗
- Melissa Anne McIntyre · 2 shared papers, 2025–2026 · strength 0.70
- Paper Modelling the impact of tumour hypoxia on proton therapy and concurrent chemotherapy on locally advanced pancreatic can… DOI 10.1088/1361-6560/ae273b↗
- Paper Modelling of dose-escalated proton beam therapy for Locally Advanced Pancreatic Cancer using simulated phantoms. DOI 10.1016/j.ejmp.2026.105758↗
- Alexander H. Staudacher · 1 shared paper, 2022 · strength 0.16
- Mikaela Dell’Oro · 1 shared paper, 2020 · strength 0.16
- Michala Short · 1 shared paper, 2020 · strength 0.16
- Barry Allen · 1 shared paper, 2020 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.